Small Fiber Neuropathy Diagnosis Didn't Change Pain Burden
Key Takeaways
- In a Dutch tertiary-center SFN cohort followed for 3 to 6 months after diagnosis, pain intensity and EQ-5D-5L quality of life did not significantly change.
- Total societal costs and patient and family costs were statistically unchanged over follow-up; productivity losses were unchanged in pairwise comparisons, although the authors also reported a lower 3-month estimate in fully adjusted GLMM analysis.
- Medical specialist contacts and specialist-related costs were significantly lower after diagnostic confirmation.
- The proportion of patients 'feeling good' increased from 50% at baseline to 71.6% at 6 months.
In a Kool et al. analysis of confirmed small fiber neuropathy before and after diagnosis, investigators conducted a single-center observational within-subject comparison at the small fiber neuropathy (SFN) expertise center in Maastricht, the Netherlands, with diagnostic confirmation rather than treatment as the exposure of interest. Eighty-four patients with confirmed SFN completed paired pre- and postdiagnosis questionnaires, and the waitlist baseline was collected about 7 months before consultation and diagnosis. Diagnosis followed the Besta criteria and a standardized workup with temperature threshold testing (TTT), skin biopsy for intraepidermal nerve fiber density (IENFD), and nerve conduction studies (NCS) to exclude large-fiber involvement. Outcomes came from resource-use and productivity questionnaires, pain scores on a numeric rating scale (NRS), and quality of life (QoL) scores on the EuroQol 5D 5-level instrument (EQ-5D-5L). This Dutch tertiary-center setting is important when considering whether the cost patterns would translate to North American care pathways.
After diagnosis, specialist use and societal costs after confirmed small fiber neuropathy diagnosis showed the clearest change in utilization, with mean medical specialist costs falling from €397.01 before diagnosis to €238.86 at 3 months and €317.10 at 6 months; both follow-up comparisons were significant. Specialist contacts also declined after confirmation. Total healthcare spending appeared lower in the short term, but that difference was not sustained at 6 months.
Broader burden measures changed less over follow-up, with mean total societal costs of €7746.93 before diagnosis, €6563.27 at 3 months, and €6285.22 at 6 months, without significant differences over time. Patient and family costs, overall productivity losses in pairwise comparisons, pain intensity, and quality of life remained unchanged overall. Health perception improved after diagnosis, but no measurable shift was observed across the study's main symptom and aggregate cost domains over short-term follow-up.
Interpretation is limited because only 84 of 370 patients with confirmed SFN contributed paired pre- and postdiagnosis data, creating potential selection bias. The tertiary Dutch referral setting, along with underrepresentation of secondary causes such as diabetes mellitus, may also limit generalizability outside similar healthcare systems. Healthcare use, productivity losses, and medication use were self-reported, treatment indication and subsequent management changes were not systematically recorded, follow-up was short, and the observational design does not support causal inference. These features make the findings most applicable to similar Dutch referral populations rather than directly to U.S. practice.
The authors concluded that confirmed SFN diagnosis was associated with lower specialist use and better self-perceived health, but not with short-term improvement in overall pain, standardized quality of life, or aggregate cost burden. They interpreted the pattern as reduced diagnostic uncertainty rather than broad burden reduction.
Clinician Questions
Which patients with small fiber neuropathy does this postdiagnosis burden analysis best represent?
The findings reflect adults with confirmed small fiber neuropathy seen at a tertiary expertise center in Maastricht, the Netherlands, after a standardized diagnostic workup. The authors said the tertiary Dutch setting, overrepresentation of higher educational levels, and underrepresentation of secondary causes such as diabetes mellitus may limit how broadly the findings apply to other practice settings and healthcare systems.
How was confirmed small fiber neuropathy defined in the Maastricht cohort?
Confirmed small fiber neuropathy in this cohort was based on the Besta criteria, which required at least two of the following: clinical signs of small-fiber impairment, abnormal temperature threshold testing, and reduced intraepidermal nerve fiber density on skin biopsy, with nerve conduction studies used to exclude large-fiber involvement. The standardized 1-day evaluation also included broader testing to look for an underlying cause.
Why can’t the changes after small fiber neuropathy diagnosis be linked to a specific treatment change?
The analysis compared burden before and after diagnostic confirmation rather than before and after a defined therapy. Treatment indication, initiation, discontinuation, and other pharmacologic or nonpharmacologic management changes were not systematically recorded, and the observational design means postdiagnosis changes cannot be attributed causally to diagnosis itself or to any specific management decision.
What happened to work productivity after confirmed small fiber neuropathy diagnosis?
Overall productivity losses after confirmed small fiber neuropathy diagnosis were not significantly different in pairwise before-versus-after comparisons. In fully adjusted GLMM Model 3, 3-month productivity costs were reported as lower with an estimate of −€1747.98 and a printed 95% CI of −€3258.81 to €237.15, with no 6-month difference reported.